« Return to News | Awards & Advancement

Teva appoints two to executive team

Friday, August 3, 2012 11:07 AM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has appointed Dr. Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive vice president of newly created community and institutional affairs.

De Notaristefani has over 25 years of international experience with extensive technical, operational, manufacturing and P&L experience. Most recently, De Notaristefani was at Bristol-Myers Squibb (BMS) where he served as president of technical operations and global support functions. Before joining BMS, he held several senior positions in manufacturing and supply chain at Aventis Pharmaceuticals. Earlier in his career, De Notaristefani held positions at Hoechst Marion Roussel, Marion Merrell Dow and Dow Chemical.

Yaari joined Teva in 1981 and has served as group vice president of global API, and most recently as group vice president of Teva generics systems. In his new position, Yaari will execute on Teva’s global commitment to social responsibility, philanthropy, institutional affairs and academic relations.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.